{"protocolSection": {"identificationModule": {"nctId": "NCT00635232", "orgStudyIdInfo": {"id": "PCO-C-006"}, "organization": {"fullName": "Ligand Pharmaceuticals", "class": "INDUSTRY"}, "briefTitle": "A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension", "officialTitle": "A Randomized, Double-Blind, Placebo And Active-Controlled, Parallel Group Study To Evaluate The Dose-Related Efficacy And Safety Of PS433540 In Subjects With Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-03"}, "primaryCompletionDateStruct": {"date": "2008-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-03-06", "studyFirstSubmitQcDate": "2008-03-12", "studyFirstPostDateStruct": {"date": "2008-03-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-08-09", "resultsFirstSubmitQcDate": "2011-08-10", "resultsFirstPostDateStruct": {"date": "2011-09-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-09-12", "lastUpdatePostDateStruct": {"date": "2011-09-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Ligand Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to learn which doses of PS433540 should be given to patients with high blood pressure to lower their blood pressure. This study will also examine how safe PS433540 is when taken by patients with high blood pressure. Approximately 720 patients will be evaluated so that about 375 patients will be entered into the treatment phase of the study and be given PS433540."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "High Blood Pressure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 261, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Irbesartan 300mg", "type": "ACTIVE_COMPARATOR", "description": "Irbesartan 300 mg once daily", "interventionNames": ["Drug: irbesartan"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Blinded Placebo Treatment", "interventionNames": ["Drug: placebo"]}, {"label": "PS433540 200mg", "type": "EXPERIMENTAL", "description": "PS433540 200mg once daily", "interventionNames": ["Drug: PS433540"]}, {"label": "PS433540 400mg", "type": "EXPERIMENTAL", "description": "PS433540 400mg once daily", "interventionNames": ["Drug: PS433540"]}, {"label": "PS433540 800mg", "type": "EXPERIMENTAL", "description": "PS433540 800mg once daily", "interventionNames": ["Drug: PS433540"]}], "interventions": [{"type": "DRUG", "name": "irbesartan", "description": "300 mg (2 x 150 mg capsules) once daily for 12 weeks", "armGroupLabels": ["Irbesartan 300mg"], "otherNames": ["Avapro"]}, {"type": "DRUG", "name": "placebo", "description": "placebo capsules once daily for 12 weeks", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "PS433540", "description": "200 mg (2 x 100 mg capsules) once daily for 12 weeks", "armGroupLabels": ["PS433540 200mg"]}, {"type": "DRUG", "name": "PS433540", "description": "400 mg (4 x 100 mg capsules) once daily for 12 weeks", "armGroupLabels": ["PS433540 400mg"]}, {"type": "DRUG", "name": "PS433540", "description": "800 mg (8 x 100 mg capsules) once daily for 12 weeks", "armGroupLabels": ["PS433540 800mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.", "timeFrame": "12 weeks"}, {"measure": "The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Males or females 18 - 70 years\n* Mean seated Systolic Blood Pressure (SBP) \u2265 140 mmHg and \\< 180 mmHg and mean seated Diastolic Blood Pressure (DBP) \\> 90 and \\< 109 mmHg at two consecutive qualifying visits (Visits 3/3.5 and Visit 4). The mean difference in DBP between the two consecutive qualifying visits must be \u2264 10 mmHg.\n* Women of child-bearing potential (WOCBP) must use two reliable forms of contraception if sexually active. Alternatively, female subjects must be postmenopausal (for at least 1 year).\n\nExclusion Criteria:\n\n* Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of PS433540, including cardiovascular (includes subjects who are known to have coronary artery disease), renal (including the absence of one kidney), pulmonary, hepatic, gastrointestinal (including clinically significant malabsorption), endocrine/metabolic, hematologic, neurologic and psychiatric diseases.\n* History of malignancy other than adequately treated basal cell or squamous cell skin cancer.\n* Subjects with a history of myocardial infarction or New York Heart Association (NYHA) class II-IV heart failure.\n* Subjects with a history of cerebrovascular accident or transient ischemic attack.\n* Subjects with clinically significant cardiac conduction defects, including second or third degree Atrioventricular Block (AV block), left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication.\n* Subjects with hemodynamically significant valvular disease.\n* Subjects with history of type 1 diabetes mellitus and subjects with a history of type 2 diabetes mellitus using antihyperglycemic medication (oral medication, insulin, or exenatide) are excluded.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Rene Belder, MD", "affiliation": "Ligand Pharmaceuticals", "role": "STUDY_DIRECTOR"}, {"name": "Joel Neutel, MD", "affiliation": "Orange County Research Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Advanced Clinical Research 1000 Forrest Place Suite 2 Pell City", "city": "Pell City", "state": "Alabama", "zip": "35128", "country": "United States", "geoPoint": {"lat": 33.58621, "lon": -86.28609}}, {"facility": "Premiere Pharmaceutical Research, LLC", "city": "Tempe", "state": "Arizona", "zip": "85282", "country": "United States", "geoPoint": {"lat": 33.41477, "lon": -111.90931}}, {"facility": "Genova Clinical Research AZ", "city": "Tucson", "state": "Arizona", "zip": "85741", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "Advanced Clinical Research Institute", "city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Associated Pharmaceutical Research Center", "city": "Buena Park", "state": "California", "zip": "90620", "country": "United States", "geoPoint": {"lat": 33.86751, "lon": -117.99812}}, {"facility": "Clinical Trials Research CA", "city": "Lincoln", "state": "California", "zip": "95648", "country": "United States", "geoPoint": {"lat": 38.89156, "lon": -121.29301}}, {"facility": "Long Beach Center for Clinical Research", "city": "Long Beach", "state": "California", "zip": "90806", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "National Research Institute", "city": "Los Angeles", "state": "California", "zip": "90057", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Superior Regional Research, LLC", "city": "Sacramento", "state": "California", "zip": "95825", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Orange County Research Center", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Westlake Medical Center", "city": "Westlake Village", "state": "California", "zip": "91361", "country": "United States", "geoPoint": {"lat": 34.14584, "lon": -118.80565}}, {"facility": "Univ. Clinical Research Deland, LLC.", "city": "Deland", "state": "Florida", "zip": "32720", "country": "United States", "geoPoint": {"lat": 29.02832, "lon": -81.30312}}, {"facility": "Allan Graff", "city": "Ft. Lauderdale", "state": "Florida", "zip": "33308", "country": "United States", "geoPoint": {"lat": 26.12231, "lon": -80.14338}}, {"facility": "Jacksonville Center for Clinical Research", "city": "Jacksonville", "state": "Florida", "zip": "32216", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "North County Medical", "city": "Sebastian", "state": "Florida", "zip": "32958", "country": "United States", "geoPoint": {"lat": 27.81641, "lon": -80.47061}}, {"facility": "Q Clinical Research", "city": "Decatur", "state": "Georgia", "zip": "30035", "country": "United States", "geoPoint": {"lat": 33.77483, "lon": -84.29631}}, {"facility": "Clinical Research Atlanta", "city": "Stockbridge", "state": "Georgia", "zip": "30281", "country": "United States", "geoPoint": {"lat": 33.54428, "lon": -84.23381}}, {"facility": "East-West Medical Research Institute", "city": "Honolulu", "state": "Hawaii", "zip": "96814", "country": "United States", "geoPoint": {"lat": 21.30694, "lon": -157.85833}}, {"facility": "Cedar Crosse Research Center", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Midwest Institute for Clinical Research", "city": "Indianapolis", "state": "Indiana", "zip": "46260", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "MD Medical Research", "city": "Oxon Hill", "state": "Maryland", "zip": "20745", "country": "United States", "geoPoint": {"lat": 38.80345, "lon": -76.9897}}, {"facility": "Cary Medical Research", "city": "Cary", "state": "North Carolina", "zip": "27518", "country": "United States", "geoPoint": {"lat": 35.79154, "lon": -78.78112}}, {"facility": "Metrolina Medical Research", "city": "Charlotte", "state": "North Carolina", "zip": "28209", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Unifour Medical Research NC", "city": "Hickory", "state": "North Carolina", "zip": "28601", "country": "United States", "geoPoint": {"lat": 35.73319, "lon": -81.3412}}, {"facility": "Northstate Clinical Research", "city": "Lenoir", "state": "North Carolina", "zip": "28645", "country": "United States", "geoPoint": {"lat": 35.91402, "lon": -81.53898}}, {"facility": "Triangle Medical Research NC", "city": "Raleigh", "state": "North Carolina", "zip": "27609", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Crescent Medical Research", "city": "Salisbury", "state": "North Carolina", "zip": "28144", "country": "United States", "geoPoint": {"lat": 35.67097, "lon": -80.47423}}, {"facility": "New Hanover Medical Rersearch", "city": "Wilmington", "state": "North Carolina", "zip": "28401", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "Peidmont Medical Research Associates", "city": "Winston Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "The Lindner Center", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Delaware Smith Clinic", "city": "Delaware", "state": "Ohio", "zip": "43015", "country": "United States", "geoPoint": {"lat": 40.29867, "lon": -83.06797}}, {"facility": "Smith Clinic", "city": "Marion", "state": "Ohio", "zip": "43302", "country": "United States", "geoPoint": {"lat": 40.58867, "lon": -83.12852}}, {"facility": "COR Clinical Research, L.L.C", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Brandywine Clinical Research Center", "city": "Downingtown", "state": "Pennsylvania", "zip": "19335", "country": "United States", "geoPoint": {"lat": 40.0065, "lon": -75.70327}}, {"facility": "Hypertension & Nephrology Inc", "city": "Providence", "state": "Rhode Island", "zip": "02904", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "Punzi Medical Center", "city": "Carrollton", "state": "Texas", "zip": "75006", "country": "United States", "geoPoint": {"lat": 32.95373, "lon": -96.89028}}, {"facility": "Innovative Clinical Trials", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "IMED Research PA", "city": "San Antonio", "state": "Texas", "zip": "78258", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Hampton Roads Center for Clinical Research", "city": "Norfolk", "state": "Virginia", "zip": "23502", "country": "United States", "geoPoint": {"lat": 36.84681, "lon": -76.28522}}, {"facility": "Gemini Scientific LLC", "city": "Madison", "state": "Wisconsin", "zip": "53719", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All subjects were weaned off all antihypertensive medication prior to be entered into a 4-week single-blind placebo run-in period. Subjects had to have eligible Seated systolic and diastolic BP measurements during the single-blind placebo run-in phase to be eligible for the double blind portion of the study.", "groups": [{"id": "FG000", "title": "Irbesartan 300mg", "description": "Irbesartan 300 mg once daily"}, {"id": "FG001", "title": "Placebo", "description": "Blinded Placebo Treatment"}, {"id": "FG002", "title": "PS433540 200mg", "description": "PS433540 200mg once daily"}, {"id": "FG003", "title": "PS433540 400mg", "description": "PS433540 400mg once daily"}, {"id": "FG004", "title": "PS433540 800mg", "description": "PS433540 800mg once daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "58"}, {"groupId": "FG001", "numSubjects": "59"}, {"groupId": "FG002", "numSubjects": "58"}, {"groupId": "FG003", "numSubjects": "58"}, {"groupId": "FG004", "numSubjects": "28"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "44"}, {"groupId": "FG001", "numSubjects": "39"}, {"groupId": "FG002", "numSubjects": "55"}, {"groupId": "FG003", "numSubjects": "48"}, {"groupId": "FG004", "numSubjects": "20"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "20"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "10"}, {"groupId": "FG004", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Irbesartan 300mg", "description": "Irbesartan 300 mg once daily"}, {"id": "BG001", "title": "Placebo", "description": "Blinded Placebo Treatment"}, {"id": "BG002", "title": "PS433540 200mg", "description": "PS433540 200mg once daily"}, {"id": "BG003", "title": "PS433540 400mg", "description": "PS433540 400mg once daily"}, {"id": "BG004", "title": "PS433540 800mg", "description": "PS433540 800mg once daily"}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "58"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "58"}, {"groupId": "BG003", "value": "58"}, {"groupId": "BG004", "value": "28"}, {"groupId": "BG005", "value": "261"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "50"}, {"groupId": "BG003", "value": "48"}, {"groupId": "BG004", "value": "28"}, {"groupId": "BG005", "value": "231"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "10"}, {"groupId": "BG004", "value": "0"}, {"groupId": "BG005", "value": "30"}]}]}]}, {"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.5", "spread": "8.97"}, {"groupId": "BG001", "value": "54.2", "spread": "8.12"}, {"groupId": "BG002", "value": "53.2", "spread": "10.58"}, {"groupId": "BG003", "value": "53.4", "spread": "10.71"}, {"groupId": "BG004", "value": "51.4", "spread": "9.92"}, {"groupId": "BG005", "value": "52.9", "spread": "9.66"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "27"}, {"groupId": "BG003", "value": "26"}, {"groupId": "BG004", "value": "17"}, {"groupId": "BG005", "value": "123"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "31"}, {"groupId": "BG003", "value": "32"}, {"groupId": "BG004", "value": "11"}, {"groupId": "BG005", "value": "138"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "58"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "58"}, {"groupId": "BG003", "value": "58"}, {"groupId": "BG004", "value": "28"}, {"groupId": "BG005", "value": "261"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.", "populationDescription": "The primary efficacy population was the Full Analysys Set (FAS) population= all randomized subjects who took at least one dose of the assigned study drug and had both baseline and post-baseline mean seated SBP. Both LOCF and observed-data set approach were performed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Irbesartan 300mg"}, {"id": "OG001", "title": "Placebo"}, {"id": "OG002", "title": "PS433540 200mg"}, {"id": "OG003", "title": "PS433540 400mg"}, {"id": "OG004", "title": "PS433540 800mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "58"}, {"groupId": "OG003", "value": "58"}, {"groupId": "OG004", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.7", "spread": "14.32"}, {"groupId": "OG001", "value": "1.8", "spread": "14.16"}, {"groupId": "OG002", "value": "-13.2", "spread": "13.61"}, {"groupId": "OG003", "value": "-14.2", "spread": "11.90"}, {"groupId": "OG004", "value": "-23.4", "spread": "18.70"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Seated Diastolic Blood Pressure (DBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Irbesartan 300mg"}, {"id": "OG001", "title": "Placebo"}, {"id": "OG002", "title": "PS433540 200mg"}, {"id": "OG003", "title": "PS433540 400mg"}, {"id": "OG004", "title": "PS433540 800mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "58"}, {"groupId": "OG003", "value": "58"}, {"groupId": "OG004", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.1", "spread": "9.19"}, {"groupId": "OG001", "value": "0.2", "spread": "9.68"}, {"groupId": "OG002", "value": "-7.2", "spread": "8.34"}, {"groupId": "OG003", "value": "-9.2", "spread": "9.10"}, {"groupId": "OG004", "value": "-14.3", "spread": "10.53"}]}]}]}, {"type": "SECONDARY", "title": "The Percentage of Patients Treated With Each Dose of PS433540 Who Achieved Blood Pressure Control, Defined as <140/90 mmHg, After 12 Weeks of Treatment.", "populationDescription": "Full analysis set (LOCF)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Irbesartan 300mg"}, {"id": "OG001", "title": "Placebo"}, {"id": "OG002", "title": "PS433540 200mg"}, {"id": "OG003", "title": "PS433540 400mg"}, {"id": "OG004", "title": "PS433540 800mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "58"}, {"groupId": "OG003", "value": "58"}, {"groupId": "OG004", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "21"}, {"groupId": "OG003", "value": "28"}, {"groupId": "OG004", "value": "16"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "Irbesartan 300mg", "description": "Irbesartan 300 mg once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 58, "otherNumAffected": 19, "otherNumAtRisk": 58}, {"id": "EG001", "title": "Placebo", "description": "Blinded Placebo Treatment", "seriousNumAffected": 0, "seriousNumAtRisk": 59, "otherNumAffected": 20, "otherNumAtRisk": 59}, {"id": "EG002", "title": "PS433540 200mg", "description": "PS433540 200mg once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 58, "otherNumAffected": 10, "otherNumAtRisk": 58}, {"id": "EG003", "title": "PS433540 400mg", "description": "PS433540 400mg once daily", "seriousNumAffected": 1, "seriousNumAtRisk": 58, "otherNumAffected": 25, "otherNumAtRisk": 58}, {"id": "EG004", "title": "PS433540 800mg", "description": "PS433540 800mg once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 28, "otherNumAffected": 17, "otherNumAtRisk": 28}], "seriousEvents": [{"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "reported during the placebo run-in phase- subject not on active treatment at the time of report.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 28}]}], "otherEvents": [{"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Dermatitis Contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 28}]}, {"term": "Eye Disorders", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Feces Discoloured", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Flushing", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Haemoglobin abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Hot Flush", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Hyperlipidaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Injury, Poisoning and Procedural Complications", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Musculoskeletal Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Nasal Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 28}]}, {"term": "Oedema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 28}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Respiratory Tract Congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Stress", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Tooth Abcess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Upper Respiratory Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 28}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (Unspecified)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 58}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 28}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The 800mg dose level was discontinued from further enrollment per protocol amendment due to findings from another PS433540 trial that suggested clinical benefit beyond 500mg was expected to be limited."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director of Project Management", "organization": "Ligand Pharmaceuticals", "email": "hzientek@ligand.com", "phone": "858-550-7892"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077405", "term": "Irbesartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M1786", "name": "Irbesartan", "asFound": "Prospective Cohort Study", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}